The genetic architecture of multiple myeloma

Nature Reviews Cancer

12, 335-348

DOI: 10.1038/nrc3257

Citation Report

#	Article	IF	Citations
1	Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence. Clinical Cancer Research, 2012, 18, 6260-6270.	3.2	213
2	Heat Shock Protein 90 and Role of Its Chemical Inhibitors in Treatment of Hematologic Malignancies. Pharmaceuticals, 2012, 5, 779-801.	1.7	14
3	Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. Journal of Hematology and Oncology, 2012, 5, 59.	6.9	38
4	Understanding the molecular biology of myeloma and its therapeutic implications. Expert Review of Hematology, 2012, 5, 603-617.	1.0	14
5	Cancer heterogeneity: origins and implications for genetic association studies. Trends in Genetics, 2012, 28, 538-543.	2.9	28
6	The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer Journal, 2012, 2, e96-e96.	2.8	70
7	Genomic instability in multiple myeloma: mechanisms and therapeutic implications. Expert Opinion on Biological Therapy, 2013, 13, S69-S82.	1.4	35
8	Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. British Journal of Cancer, 2013, 109, 676-685.	2.9	50
9	A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia, 2013, 27, 2056-2061.	3.3	78
10	Georgia on my mind: multiple myeloma highlights at ASH 2012. Memo - Magazine of European Medical Oncology, 2013, 6, 189-192.	0.3	1
11	Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. Expert Opinion on Biological Therapy, 2013, 13, S55-S68.	1.4	20
12	The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nature Genetics, 2013, 45, 522-525.	9.4	91
13	Myeloma: Classification and Risk Assessment. Seminars in Oncology, 2013, 40, 554-566.	0.8	24
15	Novel players in multiple myeloma pathogenesis: Role of protein kinases CK2 and GSK3. Leukemia Research, 2013, 37, 221-227.	0.4	28
16	Incorporating Novel Agents in the Management of Elderly Myeloma Patients. Current Hematologic Malignancy Reports, 2013, 8, 261-269.	1.2	4
18	Identification of a novel t(7;14) translocation in multiple myeloma resulting in overexpression of EGFR. Genes Chromosomes and Cancer, 2013, 52, 817-822.	1.5	7
19	Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood, 2013, 122, 219-226.	0.6	147
20	Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood, 2013, 121, 318-328.	0.6	112

#	Article	IF	Citations
21	MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunology, Immunotherapy, 2013, 62, 191-195.	2.0	23
22	Genomeâ€wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. American Journal of Hematology, 2013, 88, 16-23.	2.0	60
23	Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics, 2013, 102, 243-249.	1.3	15
24	Myeloma and MGUS. Medicine, 2013, 41, 295-298.	0.2	1
25	Impacto del tipo de hospital en la supervivencia de pacientes con mieloma mÃºltiple: estudio MICORE. Revista Clinica Espanola, 2013, 213, 330-335.	0.2	2
26	Fatal Splenic Rupture in a Previously Undiagnosed Multiple Myeloma: Morphological, Immunophenotypical and Molecular Cytogenetic Analyses. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, e22-e25.	0.2	6
27	Enhancing cytokine-induced killer cell therapy of multiple myeloma. Experimental Hematology, 2013, 41, 508-517.	0.2	21
28	New hope for relapsed and refractory multiple myeloma. Lancet Oncology, The, 2013, 14, 1028-1029.	5.1	6
29	The impact of the type of hospital on survival of multiple myeloma patients: The MICORE study. Revista Clínica Espanõla, 2013, 213, 330-335.	0.3	0
30	Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia, 2013, 27, 473-481.	3.3	112
31	Oncolytic myxoma virus: The path to clinic. Vaccine, 2013, 31, 4252-4258.	1.7	76
32	Multiple myeloma: so much progress, but so many unsolved questions. Haematologica, 2013, 98, 487-489.	1.7	11
33	Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia, 2013, 27, 925-931.	3.3	31
34	Targeting BRAF in Multiple Myeloma. Cancer Discovery, 2013, 3, 840-842.	7.7	15
35	miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle, 2013, 12, 3650-3662.	1.3	96
36	Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth. Clinical Cancer Research, 2013, 19, 2096-2106.	3.2	195
37	Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load. Journal of Clinical Oncology, 2013, 31, 4325-4332.	0.8	200
38	Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment. Clinical Cancer Research, 2013, 19, 6030-6038.	3.2	143

#	Article	IF	Citations
39	The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma. Clinical Cancer Research, 2013, 19, 4634-4637.	3.2	12
40	A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-Cultured with Bone Marrow Stromal Cells. Journal of Biomolecular Screening, 2013, 18, 637-646.	2.6	21
41	DNA repair pathways in human multiple myeloma. Cell Cycle, 2013, 12, 2760-2773.	1.3	52
42	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology American Society of Hematology Education Program, 2013, 2013, 478-487.	0.9	69
43	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. British Journal of Haematology, 2013, 163, 223-234.	1.2	7
44	Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discovery, 2013, 3, 862-869.	7.7	202
45	Improved accuracy of discrimination between IgM Multiple Myeloma and WaldenstrÃ¶m Macroglobulinaemia by testing for <scp>MYD</scp>88 L265P mutations. British Journal of Haematology, 2013, 161, 902-904.	1.2	33
46	A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia, 2013, 27, 1754-1757.	3.3	36
47	Pursuing the curative blueprint for early myeloma. Blood, 2013, 122, 486-490.	0.6	17
48	Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia, 2013, 27, 2351-2356.	3.3	72
49	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. Clinical Cancer Research, 2013, 19, 3130-3142.	3.2	86
50	Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood, 2013, 121, 3413-3419.	0.6	128
51	Plasma cell tumors in transplant patients. Blood, 2013, 121, 1247-1249.	0.6	8
52	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood, 2013, 122, 3591-3598.	0.6	131
53	Transplants for the elderly in myeloma. Blood, 2013, 122, 1332-1334.	0.6	7
54	Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica, 2013, 98, 1586-1592.	1.7	50
55	The t(4;14) multiple myelomas: 15 years after. Hematologie, 2013, 19, 96-111.	0.0	0
56	Myeloma Overexpressed 2 (Myeov2) Regulates L11 Subnuclear Localization through Nedd8 Modification. PLoS ONE, 2013, 8, e65285.	1.1	14

#	Article	IF	Citations
57	Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma. PLoS ONE, 2013, 8, e83252.	1.1	13
58	A Replicative Self-Renewal Model for Long-Lived Plasma Cells: Questioning Irreversible Cell Cycle Exit. Frontiers in Immunology, 2013, 4, 460.	2.2	28
59	Efficient Transient Transfection of Human Multiple Myeloma Cells by Electroporation â€“ An Appraisal. PLoS ONE, 2014, 9, e97443.	1.1	18
60	Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma. PLoS ONE, 2014, 9, e110973.	1.1	29
61	Practical guide on the use of second-line treatment in multiple myeloma. Hematologie, 2014, 20, 208-225.	0.0	0
62	Pomalidomide for the treatment of relapsedâ€“refractory multiple myeloma: a review of biological and clinical data. Expert Review of Anticancer Therapy, 2014, 14, 499-510.	1.1	19
63	The role of clonal evolution in smoldering multiple myeloma. Leukemia and Lymphoma, 2014, 55, 464-466.	0.6	0
64	Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics, 2014, 9, 1511-1520.	1.3	140
65	Next-generation sequencing in multiple myeloma: insights into the molecular heterogeneity of the disease. International Journal of Hematologic Oncology, 2014, 3, 367-376.	0.7	2
66	GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer Journal, 2014, 4, e175-e175.	2.8	46
67	Serial exome analysis of disease progression in premalignant gammopathies. Leukemia, 2014, 28, 1548-1552.	3.3	49
68	Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer Journal, 2014, 4, e191-e191.	2.8	142
69	Cyclin D1 splice site variant triggers chromosomal aberrations in healthy humans. Leukemia, 2014, 28, 721-722.	3.3	9
70	Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. Ca-A Cancer Journal for Clinicians, 2014, 64, 422-444.	157.7	85
71	Association of response endpoints with survival outcomes in multiple myeloma. Leukemia, 2014, 28, 258-268.	3.3	128
72	IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia, 2014, 28, 1647-1656.	3.3	109
73	Implications of Heterogeneity in Multiple Myeloma. BioMed Research International, 2014, 2014, 1-12.	0.9	43
74	Multiple myeloma: a model for scientific and clinical progress. Hematology American Society of Hematology Education Program, 2014, 2014, 1-7.	0.9	17

#	Article	IF	Citations
75	How I treat smoldering multiple myeloma. Blood, 2014, 124, 3380-3388.	0.6	41
76	Plasma cell CD20 expression: primary aberrant expression or receptor up-regulation. Leukemia and Lymphoma, 2014, 55, 444-446.	0.6	13
77	The growing link between multiple myeloma and myeloid derived suppressor cells. Leukemia and Lymphoma, 2014, 55, 2681-2682.	0.6	6
78	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. Hematology American Society of Hematology Education Program, 2014, 2014, 255-261.	0.9	25
79	Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica, 2014, 99, 1365-1372.	1.7	65
80	Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma. Cancer Research, 2014, 74, 7418-7429.	0.4	28
81	A p53â€Dependent Tumor Suppressor Network Is Induced by Selective miRâ€125aâ€5p Inhibition in Multiple Myeloma Cells. Journal of Cellular Physiology, 2014, 229, 2106-2116.	2.0	86
82	Jumping translocations and high-risk myeloma. Blood, 2014, 123, 2442-2443.	0.6	1
83	The potential of miRNAs as biomarkers for multiple myeloma. Expert Review of Molecular Diagnostics, 2014, 14, 947-959.	1.5	23
84	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	1.7	185
85	TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood, 2014, 123, 3305-3315.	0.6	89
86	Can genome array screening replace FISH as a frontâ€line test in multiple myeloma?. Genes Chromosomes and Cancer, 2014, 53, 676-692.	1.5	11
87	The Road to Treating Smoldering Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S59-S64.	0.2	2
88	Biology and Treatment of Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S65-S70.	0.2	15
89	Asymptomatic Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S78-S86.	0.2	6
90	Prognostic value of 1p deletion for multiple myeloma: a metaâ€analysis. International Journal of Laboratory Hematology, 2014, 36, 555-565.	0.7	9
91	MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer, 2014, 14, 809.	1.1	134
92	The Genetic Architecture of Multiple Myeloma. Advances in Hematology, 2014, 2014, 1-16.	0.6	79

#	Article	IF	Citations
93	Current and potential epigenetic targets in multiple myeloma. Epigenomics, 2014, 6, 215-228.	1.0	11
94	Common progenitor cells in mature B-cell malignancies. Current Opinion in Hematology, 2014, 21, 333-340.	1.2	17
95	Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia, 2014, 28, 384-390.	3.3	252
96	Clonal evolution in hematological malignancies and therapeutic implications. Leukemia, 2014, 28, 34-43.	3.3	138
97	Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia, 2014, 28, 1705-1715.	3.3	207
98	Expression of Mucinâ€1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization. Histopathology, 2014, 64, 799-806.	1.6	7
99	Staging and prognostication of multiple myeloma. Expert Review of Hematology, 2014, 7, 21-31.	1.0	33
100	The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid typeâ€2. International Journal of Cancer, 2014, 134, 2534-2546.	2.3	86
101	Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology. European Journal of Radiology, 2014, 83, 970-974.	1.2	11
102	<scp>PI</scp>3Kâ€dependent multiple myeloma cell survival is mediated by the <scp>PIK</scp>3<scp>CA</scp> isoform. British Journal of Haematology, 2014, 166, 529-539.	1.2	17
103	International Myeloma Working Group recommendations for global myeloma care. Leukemia, 2014, 28, 981-992.	3.3	162
104	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications, 2014, 5, 2997.	5.8	741
105	Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice. Clinical Cancer Research, 2014, 20, 804-813.	3.2	29
106	Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica, 2014, 99, 353-359.	1.7	111
107	Longâ€term survival in multiple myeloma. Clinical Case Reports (discontinued), 2014, 2, 173-179.	0.2	12
108	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. Experimental Hematology, 2014, 42, 927-938.	0.2	15
109	Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica, 2014, 99, 1421-1432.	1.7	50
110	The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. British Journal of Haematology, 2014, 165, 441-454.	1.2	91

#	Article	IF	Citations
111	Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood, 2014, 123, 697-705.	0.6	184
112	Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunologic Research, 2014, 59, 188-202.	1.3	57
113	Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. BMC Immunology, 2014, 15, 3.	0.9	10
114	Overcoming bortezomib resistance in multiple myeloma. Biochemical Society Transactions, 2014, 42, 804-808.	1.6	51
115	Treatment of Smoldering Myeloma: Early or Delayed?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 5-7.	0.2	3
116	Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma. Clinical Cancer Research, 2014, 20, 3254-3260.	3.2	59
117	Understanding the multiple biological aspects leading to myeloma. Haematologica, 2014, 99, 605-612.	1.7	25
118	The Tao of myeloma. Blood, 2014, 124, 1873-1879.	0.6	60
119	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood, 2014, 123, 632-639.	0.6	98
120	Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood, 2014, 123, 2513-2517.	0.6	32
121	Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood, 2014, 123, 2504-2512.	0.6	45
122	The future of autologous stem cell transplantation in myeloma. Blood, 2014, 124, 328-333.	0.6	40
123	Curing myeloma at last: defining criteria and providing the evidence. Blood, 2014, 124, 3043-3051.	0.6	194
124	A key to the quest?. Blood, 2014, 124, 2162-2163.	0.6	1
125	PP2A inactivation by ROS accumulation. Blood, 2014, 124, 2163-2165.	0.6	13
126	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica, 2014, 99, 1611-1617.	1.7	29
127	Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing. BMC Bioinformatics, 2014, 15, S3.	1.2	1
128	Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis. BMC Bioinformatics, 2014, 15, S9.	1.2	5

#	Article	IF	Citations
129	Maintenance therapy for multiple myeloma in the era of novel agents. Hematology American Society of Hematology Education Program, 2015, 2015, 279-285.	0.9	12
130	Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leukemia Research Reports, 2015, 4, 64-69.	0.2	12
131	Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point. Haematologica, 2015, 100, e328-30.	1.7	28
134	Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood, 2015, 125, 831-840.	0.6	57
135	Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood, 2015, 125, 3049-3058.	0.6	228
136	Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood, 2015, 125, 3756-3759.	0.6	41
137	Enhancing cancer clonality analysis with integrative genomics. BMC Bioinformatics, 2015, 16, S7.	1.2	6
138	Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression. Genes Chromosomes and Cancer, 2015, 54, 692-701.	1.5	5
139	Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. Journal of Experimental and Clinical Cancer Research, 2015, 34, 102.	3.5	207
140	The 3' to 5' Exoribonuclease DIS3: From Structure and Mechanisms to Biological Functions and Role in Human Disease. Biomolecules, 2015, 5, 1515-1539.	1.8	42
141	Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability. PLoS ONE, 2015, 10, e0121581.	1.1	44
142	Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple Myeloma Cell Lines. PLoS ONE, 2015, 10, e0122689.	1.1	4
143	Deep Response in Multiple Myeloma: A Critical Review. BioMed Research International, 2015, 2015, 1-7.	0.9	32
144	Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. BioMed Research International, 2015, 2015, 1-8.	0.9	13
145	Targeted Therapies in Adult B-Cell Malignancies. BioMed Research International, 2015, 2015, 1-16.	0.9	12
146	Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland. Case Reports in Hematology, 2015, 2015, 1-5.	0.3	5
147	Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?. Oncotarget, 2015, 6, 40496-40506.	0.8	42
148	Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget, 2015, 6, 3098-3110.	0.8	69

#	Article	IF	Citations
149	Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmacogenomics and Personalized Medicine, 2015, 8, 23.	0.4	13
150	Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy. Expert Review of Anticancer Therapy, 2015, 15, 787-804.	1.1	5
152	Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. Molecular Cancer, 2015, 14, 175.	7.9	40
153	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2015, 1, 746.	3.4	266
154	Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nature Communications, 2015, 6, 8983.	5.8	296
155	Treatment of relapsed multiple myeloma. , 2015, , 65-77.		0
157	Dilemmas in Treating Smoldering Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 115-123.	0.8	19
158	Efficacy and safety of lenalidomide in relapse/refractory multiple myelomaâ€"Real life experience of a tertiary cancer center. Annals of Hematology, 2015, 94, 97-105.	0.8	11
159	Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, 793-798.	2.0	23
160	SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma. EBioMedicine, 2015, 2, 13-14.	2.7	0
161	Clinical Grade â€œSNaPshotâ€•Genetic Mutation Profiling in Multiple Myeloma. EBioMedicine, 2015, 2, 71-73.	2.7	12
162	Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Research, 2015, 25, 478-487.	2.4	118
164	Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress. Molecular and Cellular Biology, 2015, 35, 2186-2202.	1.1	53
165	Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia, 2015, 29, 2173-2183.	3.3	104
166	Novel therapeutic strategies for multiple myeloma. Experimental Hematology, 2015, 43, 732-741.	0.2	98
167	APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Communications, 2015, 6, 6997.	5.8	261
168	Mixed galactolipid anomers accentuate apoptosis of multiple myeloma cells by inducing DNA damage. Carbohydrate Research, 2015, 408, 114-118.	1.1	8
169	Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway. BMC Cancer, 2015, 15, 262.	1.1	23

#	Article	IF	Citations
170	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunology Research, 2015, 3, 881-890.	1.6	24
171	Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma. British Medical Bulletin, 2015, 113, 15-30.	2.7	16
172	Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer Journal, 2015, 5, e361-e361.	2.8	79
173	Quantitative Superresolution Microscopy Reveals Differences in Nuclear DNA Organization of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. Journal of Cellular Biochemistry, 2015, 116, 704-710.	1.2	15
174	Myeloma Propagating Cells, Drug Resistance and Relapse. Stem Cells, 2015, 33, 3205-3211.	1.4	7
175	Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution. Cancer Epidemiology, 2015, 39, 693-699.	0.8	24
176	Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 2015, 33, 3911-3920.	0.8	463
177	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocrine-Related Cancer, 2015, 22, 545-559.	1.6	11
178	The road to cure in multiple myeloma starts with smoldering disease. Expert Opinion on Orphan Drugs, 2015, 3, 653-661.	0.5	6
179	Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. British Journal of Haematology, 2015, 168, 14-25.	1.2	37
180	piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma. Leukemia, 2015, 29, 196-206.	3.3	182
181	MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia, 2015, 29, 727-738.	3.3	71
182	Targeted sequencing using a 47 gene multiple myeloma mutation panel (M³P) in â€17p high risk disease. British Journal of Haematology, 2015, 168, 507-510.	1.2	42
183	Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. Oncotarget, 2016, 7, 28868-28880.	0.8	53
184	First linevsdelayed transplantation in myeloma: Certainties and controversies. World Journal of Transplantation, 2016, 6, 321.	0.6	8
185	Cytoplasmic calcium increase via fusion with inactivated Sendai virus induces apoptosis in human multiple myeloma cells by downregulation of c-Myc oncogene. Oncotarget, 2016, 7, 36034-36048.	0.8	7
186	Disentangling the microRNA regulatorymilieuin multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. Oncotarget, 2016, 7, 2367-2378.	0.8	41
187	Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. Oncotarget, 2016, 7, 47127-47133.	0.8	7

#	Article	IF	Citations
188	Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e442-e448.	1.8	8
189	Extramedullary Plasmacytoma Mimicking Pancreatic Cancer: An Unusual Presentation. Case Reports in Oncological Medicine, 2016, 2016, 1-5.	0.2	2
190	Development of Novel Immunotherapies for Multiple Myeloma. International Journal of Molecular Sciences, 2016, 17, 1506.	1.8	22
191	Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. International Journal of Molecular Sciences, 2016, 17, 2003.	1.8	59
192	In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma. Genes, 2016, 7, 107.	1.0	17
193	Next-generation sequencing: advances and applications in cancer diagnosis. OncoTargets and Therapy, 2016, Volume 9, 7355-7365.	1.0	142
195	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). Oncotarget, 2016, 7, 9666-9679.	0.8	33
196	Novel agents in the treatment of multiple myeloma: a review about the future. Journal of Hematology and Oncology, 2016, 9, 52.	6.9	140
197	Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?. Genes Chromosomes and Cancer, 2016, 55, 710-718.	1.5	28
198	Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Current Opinion in Hematology, 2016, 23, 426-433.	1.2	33
199	Early mortality in multiple myeloma: the timeâ€dependent impact of comorbidity: A populationâ€based study in 621 realâ€life patients. American Journal of Hematology, 2016, 91, 700-704.	2.0	28
200	Cyclin D type does not influence cell cycle response to <scp>DNA</scp> damage caused by ionizing radiation in multiple myeloma tumours. British Journal of Haematology, 2016, 173, 693-704.	1.2	5
202	MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood, 2016, 128, 2599-2606.	0.6	133
204	MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood, 2016, 128, 2919-2930.	0.6	57
205	Plasma Cell Neoplasms. , 2016, , .		1
206	JUMPg: An Integrative Proteogenomics Pipeline Identifying Unannotated Proteins in Human Brain and Cancer Cells. Journal of Proteome Research, 2016, 15, 2309-2320.	1.8	76
207	Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Letters, 2016, 376, 278-283.	3.2	56
208	Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138â^'CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis. Leukemia, 2016, 30, 1869-1876.	3.3	9

#	Article	IF	Citations
209	Myeloma of the central nervous system â€“ an ongoing conundrum!. Leukemia and Lymphoma, 2016, 57, 1505-1506.	0.6	3
210	Bone marrow microenvironmental CD4â€‰+â€‰and CD8â€‰+â€‰lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma â€“ an analysis from the Austrian Myeloma Registry. Leukemia and Lymphoma, 2016, 57, 1478-1481.	0.6	8
211	Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. International Journal of Hematology, 2016, 104, 300-309.	0.7	52
212	The Future of Myeloma Therapy: One Size Does Not Fit All. Journal of Oncology Practice, 2016, 12, 295-296.	2.5	2
213	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127, 2955-2962.	0.6	686
214	A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer Journal, 2016, 6, e467-e467.	2.8	59
216	Advances in understanding prognosis in myeloma. British Journal of Haematology, 2016, 175, 367-380.	1.2	27
218	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood, 2016, 128, 1735-1744.	0.6	170
219	Factors That Regulate the Generation of Antibody-Secreting Plasma Cells. Advances in Immunology, 2016, 131, 61-99.	1.1	25
221	Multiple myeloma in the marrow: pathogenesis and treatments. Annals of the New York Academy of Sciences, 2016, 1364, 32-51.	1.8	132
222	Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer Journal, 2016, 6, e453-e453.	2.8	27
223	Applied Immunohistochemistry in the Evaluation of Skin Neoplasms. , 2016, , .		1
224	Proteomic Characterization of the World Trade Center dust-activated mdig and c-myc signaling circuit linked to multiple myeloma. Scientific Reports, 2016, 6, 36305.	1.6	19
225	Gene Expression Profiles in Myeloma: Ready for the Real World?. Clinical Cancer Research, 2016, 22, 5434-5442.	3.2	53
226	The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clinical Cancer Research, 2016, 22, 5783-5794.	3.2	81
227	Characterization of memory B cells from thymus and its impact for DLBCL classification. Experimental Hematology, 2016, 44, 982-990.e11.	0.2	3
228	Are maintenance and continuous therapies indicated for every patient with multiple myeloma?. Expert Review of Hematology, 2016, 9, 743-751.	1.0	13
229	Genomewide profiling of copyâ€‰number alteration in monoclonal gammopathy of undetermined significance. European Journal of Haematology, 2016, 97, 568-575.	1.1	24

#	Article	IF	Citations
230	Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma. Leukemia and Lymphoma, 2016, 57, 2516-2525.	0.6	18
231	Experimental treatment of multiple myeloma in the era of precision medicine. Expert Review of Precision Medicine and Drug Development, 2016, 1, 37-51.	0.4	5
232	Is it possible to cure myeloma without allogeneic transplantation?. Transfusion and Apheresis Science, 2016, 54, 63-70.	0.5	10
233	Centrosome amplification and clonal evolution in multiple myeloma: Short review. Critical Reviews in Oncology/Hematology, 2016, 98, 116-121.	2.0	4
234	A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Molecular Cancer Therapeutics, 2016, 15, 241-250.	1.9	58
235	Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. Leukemia, 2016, 30, 1094-1102.	3.3	64
236	In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by Î±4Î²1 cytoplasmic-binding proteins. Leukemia, 2016, 30, 861-872.	3.3	26
237	Molecular mechanisms in multiple myeloma drug resistance. Journal of Clinical Pathology, 2016, 69, 97-101.	1.0	51
238	Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia, 2016, 30, 423-430.	3.3	58
239	Adoptive B-cell transfer mouse model of human myeloma. Leukemia, 2016, 30, 962-966.	3.3	5
240	Search for familial clustering of multiple myeloma with any cancer. Leukemia, 2016, 30, 627-632.	3.3	36
241	RNA interference for multiple myeloma therapy: targeting signal transduction pathways. Expert Opinion on Therapeutic Targets, 2016, 20, 107-121.	1.5	16
242	Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. Cancer Biomarkers, 2017, 18, 257-263.	0.8	68
243	Safety issues and management of toxicities associated with new treatments for multiple myeloma. Expert Review of Hematology, 2017, 10, 193-205.	1.0	7
244	Genomics of Multiple Myeloma. Journal of Clinical Oncology, 2017, 35, 963-967.	0.8	85
245	Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer Journal, 2017, 7, e535-e535.	2.8	48
246	Integrated analysis of proteome, phosphotyrosineâ€proteome, tyrosineâ€kinome, and tyrosineâ€phosphatome in acute myeloid leukemia. Proteomics, 2017, 17, 1600361.	1.3	17
247	Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. Journal of Leukocyte Biology, 2017, 102, 265-275.	1.5	31

#	Article	IF	Citations
248	RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia, 2017, 31, 2104-2113.	3.3	68
249	Immunologic approaches for the treatment of multiple myeloma. Cancer Treatment Reviews, 2017, 55, 190-199.	3.4	46
250	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. Future Oncology, 2017, 13, 1181-1193.	1.1	25
251	PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4. Oncogene, 2017, 36, 4481-4497.	2.6	22
252	Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica, 2017, 102, 1432-1438.	1.7	14
253	MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death and Disease, 2017, 8, e2776-e2776.	2.7	43
254	Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma. Haematologica, 2017, 102, e317-e320.	1.7	27
255	Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. British Journal of Haematology, 2017, 178, 196-208.	1.2	17
256	RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia, 2017, 31, 1706-1714.	3.3	49
257	Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia, 2017, 31, 1760-1769.	3.3	64
258	Utilizing next-generation sequencing in the management of multiple myeloma. Expert Review of Molecular Diagnostics, 2017, 17, 653-663.	1.5	28
259	Myeloma and MGUS. Medicine, 2017, 45, 311-317.	0.2	1
260	Which therapies will move to the front line for multiple myeloma?. Expert Review of Hematology, 2017, 10, 383-392.	1.0	14
261	Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept. American Journal of Hematology, 2017, 92, 536-541.	2.0	16
262	Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 376-381.	3.3	37
264	Evolutionary biology of high-risk multiple myeloma. Nature Reviews Cancer, 2017, 17, 543-556.	12.8	178
265	Logic programming reveals alteration of key transcription factors in multiple myeloma. Scientific Reports, 2017, 7, 9257.	1.6	20
266	Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nature Communications, 2017, 8, 268.	5.8	277

#	Article	IF	Citations
267	Multiple myeloma. Nature Reviews Disease Primers, 2017, 3, 17046.	18.1	812
268	Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow. Cancer Immunology Research, 2017, 5, 744-754.	1.6	17
269	Systemic virotherapy for multiple myeloma. Expert Opinion on Biological Therapy, 2017, 17, 1-13.	1.4	11
270	The proteasome and proteasome inhibitors in multiple myeloma. Cancer and Metastasis Reviews, 2017, 36, 561-584.	2.7	229
271	Expressed fusion gene landscape and its impact in multiple myeloma. Nature Communications, 2017, 8, 1893.	5.8	31
272	3D genome of multiple myeloma reveals spatial genome disorganization associated with copy number variations. Nature Communications, 2017, 8, 1937.	5.8	99
273	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia, 2017, , .	3.3	9
274	Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. Nature Communications, 2017, 8, 1613.	5.8	45
275	A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis. Experimental Hematology, 2017, 53, 31-42.	0.2	15
276	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 555-562.	0.2	28
277	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Modern Pathology, 2017, 30, 1338-1366.	2.9	36
278	The possible role of burden of therapy on the risk of myeloma extramedullary spread. Annals of Hematology, 2017, 96, 73-80.	0.8	34
279	Panobinostat for the management of multiple myeloma. Future Oncology, 2017, 13, 477-488.	1.1	42
280	Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia, 2017, 31, 1123-1135.	3.3	61
281	The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia, 2017, 31, 853-860.	3.3	72
282	Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. Oncogene, 2017, 36, 2105-2115.	2.6	34
283	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. Hematological Oncology, 2017, 35, 734-740.	0.8	6
284	Distinct and shared threeâ€dimensional chromosome organization patterns in lymphocytes, monoclonal gammopathy of undetermined significance and multiple myeloma. International Journal of Cancer, 2017, 140, 400-410.	2.3	13

#	Article	IF	Citations
285	Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia, 2017, 31, 645-653.	3.3	47
286	Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia, 2017, 31, 637-644.	3.3	27
287	Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS. Leukemia, 2017, 31, 922-933.	3.3	16
288	Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 262-268.	2.0	33
289	DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. Neoplasia, 2017, 19, 972-981.	2.3	18
290	Integration of Genomics Into Treatment: Are We There Yet?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 569-574.	1.8	2
291	Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. Oncology Letters, 2017, 14, 4372-4378.	0.8	9
292	Role of Galectins in Multiple Myeloma. International Journal of Molecular Sciences, 2017, 18, 2740.	1.8	21
293	Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma. Frontiers in Immunology, 2017, 8, 954.	2.2	30
294	Long non-coding RNAs in B-cell malignancies: a comprehensive overview. Oncotarget, 2017, 8, 60605-60623.	0.8	25
295	A p110Î´-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-Î²B. International Journal of Oncology, 2017, 50, 1711-1720.	1.4	3
296	Towards integrated oncogenic marker recognition through mutual informationâ€based statistically significant feature extraction: an association rule mining based study on cancer expression and methylation profiles. Quantitative Biology, 2017, 5, 302-327.	0.3	16
297	Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Management and Research, 2017, Volume 9, 307-314.	0.9	25
298	A Hybrid Computation Model to Describe the Progression of Multiple Myeloma and Its Intra-Clonal Heterogeneity. Computation, 2017, 5, 16.	1.0	15
299	Chromothripsis in Treatment Resistance in Multiple Myeloma. Genomics and Informatics, 2017, 15, 87-97.	0.4	13
300	MCL1 gene coâ€expression module stratifies multiple myeloma and predicts response to proteasome inhibitorâ€based therapy. Genes Chromosomes and Cancer, 2018, 57, 420-429.	1.5	13
301	Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia, 2018, 32, 2435-2444.	3.3	26
302	Short overview on the current standard of treatment in newly diagnosed multiple myeloma. Memo - Magazine of European Medical Oncology, 2018, 11, 59-64.	0.3	8

#	Article	IF	Citations
303	Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 734-751.	1.3	9
304	Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 235-248.	0.2	11
306	Epidemiology and Pathophysiology of Multiple Myeloma. Hematologic Malignancies, 2018, , 1-15.	0.2	1
307	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. Hematologic Malignancies, 2018, , 73-96.	0.2	1
308	Identification of novel fusion transcripts in multiple myeloma. Journal of Clinical Pathology, 2018, 71, 708-712.	1.0	5
309	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. Blood Cancer Journal, 2018, 8, 20.	2.8	19
310	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. Expert Review of Hematology, 2018, 11, 219-237.	1.0	28
311	Nanotherapeutics for multiple myeloma. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1526.	3.3	9
312	Expression of genes MAGE-A3 MAGE-C1, NY-ESO-1 and SSX1 in patients with multiple myeloma at the General Hospital of Mexico. Revista MÃ©dica Del Hospital General De MÃ©xico, 2018, 81, 86-92.	0.0	0
313	Overcoming multiple myeloma drug resistance in the era of cancer â€˜omicsâ€™. Leukemia and Lymphoma, 2018, 59, 542-561.	0.6	34
314	Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia, 2018, 32, 111-119.	3.3	42
315	Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia, 2018, 32, 120-130.	3.3	57
316	Identifying the biomarker potential of telomerase activity and shelterin complex molecule, telomeric repeat binding factor 2 (TERF2), in multiple myeloma. Leukemia and Lymphoma, 2018, 59, 1677-1689.	0.6	12
318	Epigenetics in multiple myeloma: From mechanisms to therapy. Seminars in Cancer Biology, 2018, 51, 101-115.	4.3	59
319	Minimal residual disease analysis in myeloma â€“ when, why and where. Leukemia and Lymphoma, 2018, 59, 1772-1784.	0.6	19
320	Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain. Experimental Hematology, 2018, 57, 42-49.e1.	0.2	2
321	Epigenetic silencing of EVL/miR-342 in multiple myeloma. Translational Research, 2018, 192, 46-53.	2.2	14
322	Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia, 2018, 32, 1043-1047.	3.3	87

#	Article	IF	Citations
323	Syndecan-1 promotes Wnt/Î²-catenin signaling in multiple myeloma by presenting Wnts and R-spondins. Blood, 2018, 131, 982-994.	0.6	68
324	Targeted drug delivery for tumor therapy inside the bone marrow. Biomaterials, 2018, 155, 191-202.	5.7	57
325	Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia. Medicine (United States), 2018, 97, e13103.	0.4	3
326	Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO Precision Oncology, 2018, 2018, 1-17.	1.5	20
327	Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and WaldenstrÃ¶m Macroglobulinemia. Journal of Global Oncology, 2018, 4, 1-8.	0.5	3
328	TPO-logy accepted. Blood, 2018, 132, 555-557.	0.6	7
329	A multiple myeloma that progressed as type I cryoglobulinemia with skin ulcers and foot necrosis. Medicine (United States), 2018, 97, e12355.	0.4	10
330	Mouse models of multiple myeloma: technologic platforms and perspectives. Oncotarget, 2018, 9, 20119-20133.	0.8	35
331	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	1.5	20
332	Pathology and Genetics of Multiple Myeloma. , 2018, , .		0
333	Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer Journal, 2018, 8, 117.	2.8	74
334	The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies. Frontiers in Oncology, 2018, 8, 550.	1.3	52
335	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nature Medicine, 2018, 24, 1867-1876.	15.2	179
336	Osteoblast suppression in multiple myeloma bone disease. Journal of Bone Oncology, 2018, 13, 62-70.	1.0	28
337	The genetic landscape of 5T models for multiple myeloma. Scientific Reports, 2018, 8, 15030.	1.6	15
338	Clinical impact of MYC abnormalities in plasma cell myeloma. Cancer Genetics, 2018, 228-229, 115-126.	0.2	3
339	Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. Scientific Reports, 2018, 8, 13522.	1.6	11
340	Targeting EZH2 in Multiple Myelomaâ€"Multifaceted Anti-Tumor Activity. Epigenomes, 2018, 2, 16.	0.8	18

#	Article	IF	Citations
341	Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Frontiers in Immunology, 2018, 9, 1821.	2.2	205
342	Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2263-2273.	1.2	10
343	Ubiquitination and DNA Repair in Multiple Myeloma. , 2018, , .		0
344	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Advances, 2018, 2, 2607-2618.	2.5	33
345	Multiple Myeloma: Detecting Genetic Changes Through Bone Marrow Biopsy and the Influence on Care. Clinical Journal of Oncology Nursing, 2018, 22, 263-265.	0.3	1
347	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia, 2018, 32, 2604-2616.	3.3	137
349	Whole Exome Sequencing in Multiple Myeloma to Identify Somatic Single Nucleotide Variants and Key Translocations Involving Immunoglobulin Loci and MYC. Methods in Molecular Biology, 2018, 1792, 71-95.	0.4	5
351	How I treat the young patient with multiple myeloma. Blood, 2018, 132, 1114-1124.	0.6	38
352	Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic. Expert Review of Hematology, 2018, 11, 513-523.	1.0	8
353	A Rapid and Robust Protocol for Reduced Representation Bisulfite Sequencing in Multiple Myeloma. Methods in Molecular Biology, 2018, 1792, 179-191.	0.4	4
354	Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma. Annals of Hematology, 2018, 97, 2447-2454.	0.8	4
355	Progress in the Classification of Hematopoietic and Lymphoid Neoplasms. , 2018, , 763-773.		0
356	Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology, 2017, 8, 1936.	2.2	39
357	Long Non-Coding RNAs in Multiple Myeloma. Genes, 2018, 9, 69.	1.0	22
358	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. International Journal of Molecular Sciences, 2018, 19, 2087.	1.8	14
359	MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. BMC Cancer, 2018, 18, 724.	1.1	26
360	A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. Scientific Reports, 2018, 8, 6557.	1.6	34
361	A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer Journal, 2018, 8, 35.	2.8	41

#	Article	IF	Citations
362	Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse. Molecular Cytogenetics, 2018, 11, 7.	0.4	11
363	Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression. BMC Cancer, 2018, 18, 551.	1.1	11
364	Genomic patterns of progression in smoldering multiple myeloma. Nature Communications, 2018, 9, 3363.	5.8	163
365	Detailing the genomic landscape of myeloma. Blood, 2018, 132, 554-555.	0.6	2
366	High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma. Journal of Molecular Diagnostics, 2018, 20, 777-788.	1.2	13
367	Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data. Molecular Genetics and Genomics, 2018, 293, 1217-1229.	1.0	0
368	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood, 2018, 132, 587-597.	0.6	335
369	Multiple Myeloma and Other Plasma Cell Neoplasms. , 2018, , 383-403.		0
370	Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia, 2018, 32, 2636-2647.	3.3	94
371	Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia, 2019, 33, 457-468.	3.3	96
372	miR-22 suppresses DNA ligase III addiction in multiple myeloma. Leukemia, 2019, 33, 487-498.	3.3	39
373	Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2019, 24, 133-152.	1.0	20
374	High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. Journal of Clinical Medicine, 2019, 8, 997.	1.0	45
375	Role of Standard Magnetic Resonance Imaging. , 2019, , 39-72.		0
376	Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma. Cancer Science, 2019, 110, 2600-2606.	1.7	6
378	HDAC6â€'selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma. International Journal of Oncology, 2019, 55, 499-512.	1.4	9
379	A practical guide for mutational signature analysis in hematological malignancies. Nature Communications, 2019, 10, 2969.	5.8	145
380	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e616-e629.	2.2	42

#	Article	IF	Citations
382	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. Expert Review of Anticancer Therapy, 2019, 19, 889-898.	1.1	6
384	MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1. Human Cell, 2019, 32, 529-539.	1.2	8
385	1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China. Oncologist, 2019, 24, e1132-e1140.	1.9	15
386	Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nature Communications, 2019, 10, 3835.	5.8	183
387	Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations?. Frontiers in Genetics, 2019, 10, 785.	1.1	3
388	Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Frontiers in Oncology, 2018, 8, 665.	1.3	47
389	Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16). Genes Chromosomes and Cancer, 2019, 58, 516-520.	1.5	4
390	The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia, 2019, 33, 863-883.	3.3	45
392	Germline Risk Contribution to Genomic Instability in Multiple Myeloma. Frontiers in Genetics, 2019, 10, 424.	1.1	10
393	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. Clinical Epigenetics, 2019, 11, 71.	1.8	23
394	The treatment of multiple myeloma in an era of precision medicine. Expert Review of Precision Medicine and Drug Development, 2019, 4, 153-162.	0.4	3
395	miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. Molecular Therapy - Nucleic Acids, 2019, 16, 391-406.	2.3	30
396	Tissue engineered models of healthy and malignant human bone marrow. Advanced Drug Delivery Reviews, 2019, 140, 78-92.	6.6	18
397	Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. Annals of Hematology, 2019, 98, 1457-1466.	0.8	15
398	piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene, 2019, 38, 5227-5238.	2.6	98
399	Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer Journal, 2019, 9, 39.	2.8	38
400	Epigeneticâ€Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease. JBMR Plus, 2019, 3, e10183.	1.3	19
401	The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. International Journal of Molecular Sciences, 2019, 20, 1248.	1.8	54

#	Article	IF	Citations
402	Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. Expert Opinion on Investigational Drugs, 2019, 28, 445-462.	1.9	13
403	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 332-344.	0.2	16
404	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer Journal, 2019, 9, 15.	2.8	30
405	Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia, 2019, 33, 1063-1075.	3.3	119
406	Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccineâ€“Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunology Research, 2019, 7, 658-669.	1.6	12
407	Physicians, paraproteins and progress: diagnosis and management of myeloma. British Journal of Hospital Medicine (London, England: 2005), 2019, 80, 91-98.	0.2	6
408	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Advances, 2019, 3, 4095-4103.	2.5	17
409	GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial. Pharmacology Research and Perspectives, 2019, 7, e00526.	1.1	12
410	DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling. Haematologica, 2019, 104, 155-165.	1.7	26
411	Lower number of 5-hydroxymethylcytosine-expressing cells in plasma cell myeloma than in reactive plasma cell hyperplasia: a useful immunohistochemical approach for identification of neoplastic plasma cells. Pathology, 2019, 51, 81-85.	0.3	0
412	Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood, 2019, 133, 660-675.	0.6	136
413	Evolution of Cancer Progression in the Context of Darwinism. Anticancer Research, 2019, 39, 1-16.	0.5	23
415	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 57-73.	5.1	245
416	Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma. Immunology Letters, 2019, 205, 40-50.	1.1	11
417	Factors Regulating microRNA Expression and Function in Multiple Myeloma. Non-coding RNA, 2019, 5, 9.	1.3	29
418	Molecular signatures of multiple myeloma progression through single cell RNA-Seq. Blood Cancer Journal, 2019, 9, 2.	2.8	74
419	Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance. European Journal of Pharmacology, 2019, 842, 89-98.	1.7	21
420	Archival May-GrÃ¼nwaldâ€“Giemsa-Stained Bone Marrow Smears Are an Eligible Source for Molecular DNA Research. Biopreservation and Biobanking, 2019, 17, 274-281.	0.5	2

#	Article	IF	Citations
421	Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma. Haematologica, 2020, 105, 1055-1066.	1.7	42
422	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 2020, 34, 234-244.	3.3	80
423	The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?. Cancer Genetics, 2020, 242, 15-24.	0.2	32
424	IgA plasma cell neoplasms are characterized by poorer long-term survival and increased genomic complexity compared to IgG neoplasms. Annals of Diagnostic Pathology, 2020, 44, 151449.	0.6	6
425	Emerging biomarkers in Multiple Myeloma: A review. Clinica Chimica Acta, 2020, 503, 45-53.	0.5	39
426	A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 337-351.	1.4	30
427	Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma. JAMA Oncology, 2020, 6, 425.	3.4	41
428	Extramedullary multiple myeloma. Leukemia, 2020, 34, 1-20.	3.3	140
429	A probable case of multiple myeloma from Bronze Age China. International Journal of Paleopathology, 2020, 31, 64-70.	0.8	3
430	Practical approach to the management of smoldering myeloma. Current Opinion in Oncology, 2020, 32, 656-663.	1.1	0
431	Epigenetic Aberrations in Multiple Myeloma. Cancers, 2020, 12, 2996.	1.7	24
432	Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia, 2020, 34, 3111-3125.	3.3	39
433	Accelerated single cell seeding in relapsed multiple myeloma. Nature Communications, 2020, 11, 3617.	5.8	41
434	The Acidic Microenvironment: Is It a Phenotype of All Cancers? A Focus on Multiple Myeloma and Some Analogies with Diabetes Mellitus. Cancers, 2020, 12, 3226.	1.7	17
435	A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. Genes, 2020, 11, 1453.	1.0	2
436	Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. Cancers, 2020, 12, 2149.	1.7	6
437	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 108.	6.9	20
438	A Perturbation based Algorithm for Inference of Gene Regulatory Networks for Multiple Myeloma. , 2020, , .		1

#	Article	IF	Citations
439	Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. Cancer Cell International, 2020, 20, 403.	1.8	11
440	The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients. Cancers, 2020, 12, 2569.	1.7	21
441	Long Noncoding RNA LUCAT1 Promotes Multiple Myeloma Cell Growth by Regulating the TGF-Î² Signaling Pathway. Technology in Cancer Research and Treatment, 2020, 19, 153303382094577.	0.8	8
442	Copy number evolution and its relationship with patient outcomeâ€"an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 2021, 35, 2043-2053.	3.3	23
443	Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. Blood Advances, 2020, 4, 5616-5630.	2.5	10
444	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. Clinical Epigenetics, 2020, 12, 163.	1.8	9
445	IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. European Journal of Haematology, 2020, 105, 326-334.	1.1	6
446	Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort. British Journal of Haematology, 2020, 191, 755-763.	1.2	0
447	Upregulated expression and function of the ‹b›Î±‹/b›4‹b›Î²‹/b›1 integrin in multiple myeloma cells resistant to bortezomib. Journal of Pathology, 2020, 252, 29-40.	2.1	17
448	Genomic Instability in Multiple Myeloma. Trends in Cancer, 2020, 6, 858-873.	3.8	18
449	Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?. Frontiers in Oncology, 2020, 10, 189.	1.3	33
450	PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely. Biology of Blood and Marrow Transplantation, 2020, 26, 1273-1279.	2.0	8
451	Developments in consolidation and maintenance strategies in post-remission multiple myeloma. Expert Review of Hematology, 2020, 13, 351-362.	1.0	4
452	The Role of Early Intervention in High-Risk Smoldering Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 355-363.	1.8	11
453	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. Journal of Oncology, 2020, 2020, 1-11.	0.6	46
454	Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Review of Precision Medicine and Drug Development, 2020, 5, 67-85.	0.4	7
455	CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma. Clinical Immunology, 2020, 213, 108363.	1.4	8
456	Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models. Cancer Genomics and Proteomics, 2020, 17, 321-334.	1.0	2

#	Article	IF	Citations
458	The Possible Role of Point Mutations and Activation of the CDC27 Gene in Progression of Multiple Myeloma. Meta Gene, 2020, 26, 100761.	0.3	2
459	Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. Haematologica, 2020, 106, 185-195.	1.7	33
460	C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma. Oncogene, 2020, 39, 3354-3366.	2.6	10
461	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17.	2.8	75
462	Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. Blood Cancer Journal, 2020, 10, 18.	2.8	14
463	Magnetic Nanoheterostructures. Nanomedicine and Nanotoxicology, 2020, , .	0.1	3
464	Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers, 2020, 12, 407.	1.7	136
465	First-in-Human Phase I Study of ABBV-838, an Antibodyâ€“Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2020, 26, 2308-2317.	3.2	20
466	Tracking myeloma tumor DNA in peripheral blood. Best Practice and Research in Clinical Haematology, 2020, 33, 101146.	0.7	7
467	Second malignancies in multiple myeloma; emerging patterns and future directions. Best Practice and Research in Clinical Haematology, 2020, 33, 101144.	0.7	27
468	GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS ONE, 2020, 15, e0228408.	1.1	2
469	Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. Cells, 2020, 9, 287.	1.8	37
470	Genomic profiling of multiple myeloma: New insights and modern technologies. Best Practice and Research in Clinical Haematology, 2020, 33, 101153.	0.7	7
471	Reconstructing the evolutionary history of multiple myeloma. Best Practice and Research in Clinical Haematology, 2020, 33, 101145.	0.7	21
472	Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e352-e367.	0.2	23
473	Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases. Frontiers in Physiology, 2020, 11, 361.	1.3	24
474	Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma. BMC Cancer, 2020, 20, 269.	1.1	10
475	Liquid biopsies for multiple myeloma in a time of precision medicine. Journal of Molecular Medicine, 2020, 98, 513-525.	1.7	18

#	Article	IF	Citations
476	The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation. Cancers, 2020, 12, 921.	1.7	15
477	Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 358-365.	0.2	3
478	Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma. Cancers, 2020, 12, 782.	1.7	6
479	Timing the initiation of multiple myeloma. Nature Communications, 2020, 11, 1917.	5.8	99
480	Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. Clinical Cancer Research, 2021, 27, 15-23.	3.2	20
481	Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects. Pathology Research and Practice, 2021, 218, 153317.	1.0	5
482	Monitoring treatment response and disease progression in myeloma with circulating cellâ€free DNA. European Journal of Haematology, 2021, 106, 230-240.	1.1	21
483	The clonal evolution during long-term clinical course of multiple myeloma. International Journal of Hematology, 2021, 113, 279-284.	0.7	3
484	Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma. Cancers, 2021, 13, 396.	1.7	17
485	What Is New in the Treatment of Smoldering Multiple Myeloma?. Journal of Clinical Medicine, 2021, 10, 421.	1.0	7
486	Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression. Cancers, 2021, 13, 517.	1.7	12
487	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLoS Medicine, 2021, 18, e1003454.	3.9	18
488	A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. Annals of Hematology, 2021, 100, 437-443.	0.8	11
489	DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment. Cancers, 2021, 13, 504.	1.7	14
490	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Seminars in Hematology, 2021, 58, 45-55.	1.8	8
491	Multiple myeloma. Lancet, The, 2021, 397, 410-427.	6.3	349
492	Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma. PLoS ONE, 2021, 16, e0246322.	1.1	5
493	Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. Leukemia, 2021, 35, 1438-1450.	3.3	28

#	Article	IF	Citations
494	The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma. Haematologica, 2022, 107, 721-732.	1.7	17
495	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer Journal, 2021, 11, 26.	2.8	10
496	Mutation-dependent treatment approaches for patients with complex multiple myeloma. Expert Review of Precision Medicine and Drug Development, 2021, 6, 189-201.	0.4	0
497	Targeting NSD2-mediated SRC-3 liquidâ€“liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nature Communications, 2021, 12, 1022.	5.8	37
498	Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention. Frontiers in Immunology, 2021, 12, 632564.	2.2	8
499	Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. Expert Review of Molecular Diagnostics, 2021, 21, 161-173.	1.5	2
500	DNA-double strand breaks enhance the expression of major histocompatibility complex class II through the ATM-NF-Îºl'-IRF1-CIITA pathway. Cancer Gene Therapy, 2022, 29, 225-240.	2.2	10
501	Game of Bones: How Myeloma Manipulates Its Microenvironment. Frontiers in Oncology, 2020, 10, 625199.	1.3	24
502	Anti-Cancer Activity of Curcumin on Multiple Myeloma. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 575-586.	0.9	23
504	Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition. Npj Genomic Medicine, 2021, 6, 23.	1.7	6
505	Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells. Scientific Reports, 2021, 11, 5216.	1.6	3
506	Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. , 2021, 9, e001803.		12
507	Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14). Pathology and Oncology Research, 2021, 27, 606567.	0.9	0
508	COX2 confers bone marrow stromal cells to promoting TNFÎ±/TNFR1Î²-mediated myeloma cell growth and adhesion. Cellular Oncology (Dordrecht), 2021, 44, 643-659.	2.1	3
509	How to Treat High-Risk Myeloma at Diagnosis and Relapse. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 291-309.	1.8	27
510	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 243.e1-243.e6.	0.6	1
511	A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. Scientific Reports, 2021, 11, 7009.	1.6	2
512	Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion. Cancer Cell International, 2021, 21, 187.	1.8	6

#	Article	IF	Citations
513	The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma. Cancers, 2021, 13, 1976.	1.7	9
514	Pathway-Directed Therapy in Multiple Myeloma. Cancers, 2021, 13, 1668.	1.7	15
515	3D Models of Surrogate Multiple Myeloma Bone Marrow Microenvironments: Insights on Disease Pathophysiology and Patient-Specific Response to Drugs. , 0, , .		0
516	Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma. Cancers, 2021, 13, 1969.	1.7	12
517	Genomic Instability in Multiple Myeloma: A â€œNon-Coding RNAâ€•Perspective. Cancers, 2021, 13, 2127.	1.7	8
518	Extramedullary multiple myeloma patient derived orthotopic xenograft with high disturbed genome: combined exhaustive molecular and therapeutic studies. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	5
519	Single nucleotide polymorphism arrayâ€based signature of low hypodiploidy in acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2021, 60, 604-615.	1.5	12
520	The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology. Cancers, 2021, 13, 2326.	1.7	24
521	From Bench to Bedside. Cancer Journal (Sudbury, Mass), 2021, 27, 213-221.	1.0	1
522	Myeloma and MGUS. Medicine, 2021, 49, 307-313.	0.2	0
523	Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). American Journal of Hematology, 2021, 96, 925-933.	2.0	7
524	The Immunityâ€malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells. FEBS Journal, 2022, 289, 4383-4397.	2.2	7
525	Animal Models of Multiple Myeloma Bone Disease. Frontiers in Genetics, 2021, 12, 640954.	1.1	5
526	Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients. Frontiers in Oncology, 2021, 11, 682658.	1.3	2
527	Management of patients with difficult-to-treat multiple myeloma. Future Oncology, 2021, 17, 2089-2105.	1.1	1
528	Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy. Cancer Biology and Therapy, 2021, 22, 404-412.	1.5	4
529	Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma. Genes Chromosomes and Cancer, 2021, 60, 668-677.	1.5	0
530	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	1.7	22

#	Article	IF	Citations
532	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. Expert Review of Molecular Diagnostics, 2021, 21, 757-766.	1.5	4
533	TPQCI: A topology potential-based method to quantify functional influence of copy number variations. Methods, 2021, 192, 46-56.	1.9	5
534	Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications. Cancers, 2021, 13, 4069.	1.7	4
535	Does myeloma genetic have an effect on stem cell mobilization?. Transfusion and Apheresis Science, 2021, , 103249.	0.5	0
538	Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6479-6490.	3.2	9
539	Harnessing the Immune System to Fight Multiple Myeloma. Cancers, 2021, 13, 4546.	1.7	10
540	Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity. Cancers, 2021, 13, 4898.	1.7	8
541	In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET. EJNMMI Research, 2021, 11, 97.	1.1	4
542	Prognostic and predictive biomarker developments in multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 151.	6.9	49
543	The expression of multiple cancer/testis antigens can potentially be used to detect circulating disease and clonal evolution in the peripheral blood of multiple myeloma patients. Blood Research, 2021, 56, 156-165.	0.5	1
544	Ribosomal proteins as distinct â€œpassengersâ€•of microvesicles: new semantics in myeloma and mesenchymal stem cells' communication. Translational Research, 2021, 236, 117-132.	2.2	5
545	Roadmap to cure multiple myeloma. Cancer Treatment Reviews, 2021, 100, 102284.	3.4	44
546	Status of Next-Generation Sequencing-Based Genetic Diagnosis in Hematologic Malignancies in Korea (2017-2018). Laboratory Medicine Online, 2021, 11, 25-31.	0.0	1
547	Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways. Theranostics, 2021, 11, 7735-7754.	4.6	8
548	Artificial Intelligence in Plasma Cell Myeloma: Neural Networks and Support Vector Machines in the Classification of Plasma Cell Myeloma Data at Diagnosis. Journal of Pathology Informatics, 2021, 12, 35.	0.8	3
549	Highâ€risk cytogenetics in multiple myeloma: Further scrutiny of deletions within the IGH gene region enhances risk stratification. Genes Chromosomes and Cancer, 2020, 59, 569-574.	1.5	6
550	Multiple Myeloma: Role of Magnetic Nanoparticles. Nanomedicine and Nanotoxicology, 2020, , 479-494.	0.1	2
551	A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. HemaSphere, 2020, 4, e502.	1.2	10

#	Article	IF	Citations
554	Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trialâ€unfit patients and subsequent therapy. British Journal of Haematology, 2021, 193, 101-112.	1.2	12
555	Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to antiâ€tumor activity in multiple myeloma. European Journal of Haematology, 2021, 106, 90-99.	1.1	20
556	Bone marrow transplantation generates T cellâ€“dependent control of myeloma in mice. Journal of Clinical Investigation, 2018, 129, 106-121.	3.9	49
557	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. Hematology American Society of Hematology Education Program, 2014, 2014, 255-261.	0.9	16
558	Recent advances in understanding multiple myeloma. F1000Research, 2016, 5, 2053.	0.8	13
559	Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. PLoS ONE, 2017, 12, e0174835.	1.1	31
560	Development of novel methods for non-canonical myeloma protein analysis with an innovative adaptation of immunofixation electrophoresis, native top-down mass spectrometry, and middle-down de novo sequencing. Clinical Chemistry and Laboratory Medicine, 2021, 59, 653-661.	1.4	7
562	Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget, 2016, 7, 60698-60711.	0.8	137
563	The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFÎºB signalling pathway. Oncotarget, 2015, 6, 17314-17327.	0.8	9
564	Inactivation of CK1Î± in multiple myeloma empowers drug cytotoxicity by affecting AKT and Î²-catenin survival signaling pathways. Oncotarget, 2017, 8, 14604-14619.	0.8	30
565	The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget, 2017, 8, 27854-27867.	0.8	25
566	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget, 2017, 8, 56338-56350.	0.8	35
567	Hyperhaploid karyotypes in multiple myeloma. Oncotarget, 2017, 8, 78259-78260.	0.8	4
568	Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget, 2014, 5, 5686-5699.	0.8	59
569	The genomic features associated with high-risk multiple myeloma. Oncotarget, 2018, 9, 35478-35479.	0.8	6
570	Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget, 2019, 10, 732-737.	0.8	13
571	Targeted drug combination therapy design based on driver genes. Oncotarget, 2019, 10, 5255-5266.	0.8	17
572	The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression. Oncotarget, 2019, 10, 5480-5491.	0.8	11

#	Article	IF	Citations
573	MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1. Oncotarget, 2020, 11, 727-739.	0.8	12
574	Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. Oncotarget, 2015, 6, 6431-6447.	0.8	23
575	miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget, 2015, 6, 12837-12861.	0.8	112
576	Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. Oncotarget, 2015, 6, 18921-18932.	0.8	45
577	Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget, 2015, 6, 19132-19147.	0.8	41
578	Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget, 2015, 6, 24205-24217.	0.8	65
579	A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget, 2015, 6, 26129-26141.	0.8	40
580	Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget, 2015, 6, 26826-26840.	0.8	47
581	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget, 2012, 3, 1246-1258.	0.8	138
582	Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget, 2016, 7, 19589-19600.	0.8	45
583	In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma. Oncotarget, 2013, 4, 242-255.	0.8	125
584	The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Oncotarget, 2016, 7, 48732-48752.	0.8	40
585	Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma. Oncotarget, 2016, 7, 38762-38774.	0.8	3
586	Comorbidity and Personalized Treatment of Multiple Myeloma in Real Clinical Practice. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 322-334.	0.1	2
587	Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. Current Cancer Therapy Reviews, 2014, 10, 70-79.	0.2	34
589	Promoter hypermethylation inï¬‚uences the suppressive role of long nonâ€‘coding RNA MEG3 in the development of multiple myeloma. Experimental and Therapeutic Medicine, 2020, 20, 637-645.	0.8	9
590	The Molecular Pathogenesis of Multiple Myeloma. Hematology Reports, 2020, 12, 9054.	0.3	9
591	Light Chain Multiple Myeloma: A Single Institution Series. Journal of Leukemia (Los Angeles, Calif), 2015, 03, .	0.1	2

#	Article	IF	Citations
592	Targeting CXCL12/CXCR4 Axis in Multiple Myeloma. Journal of Hematology & Thromboembolic Diseases, 2014, 02, .	0.1	6
593	Minimal residual disease monitoring: the new standard for treatment evaluation of haematological malignancies?. Swiss Medical Weekly, 2014, 144, w13907.	0.8	14
594	Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. ELife, 2015, 4, e07072.	2.8	17
595	Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment. Journal of Clinical Medicine, 2021, 10, 4588.	1.0	11
596	Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers, 2021, 13, 5154.	1.7	30
597	Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma. Blood Cancer Journal, 2021, 11, 166.	2.8	27
598	A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-Cultured with Bone Marrow Stromal Cells. Blood, 2012, 120, 1373-1373.	0.6	0
599	What is the Optimal Minimal?. , 2013, 10, .		0
600	Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents. Journal of the Advanced Practitioner in Oncology, 2013, 4, .	0.2	7
601	Cytogenetics of Plasma Cell Neoplasms. , 2016, , 79-97.		0
602	Immunohistology and Molecular Studies of Cutaneous B-Cell Lymphomas. , 2016, , 207-227.		0
603	Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1199-1201.	0.0	0
604	Treatment of t(4;14) and del(17p) in Multiple Myeloma. , 2018, , 59-76.		0
605	Multiple Myeloma and Other Plasma Cell Neoplasms. , 2018, , 642-663.e1.		2
606	Management of daratumumab interference in Portuguese blood transfusion medicine: A literature review about unmet needs and challenges. International Journal of Blood Transfusion and Immunohematology, 2018, 7, 1.	0.4	0
607	Prognostic Value of Genetic Markers for Efficacy Estimation of Induction Treatment Including Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 54-69.	0.1	1
608	Plasmazellneoplasien. , 2019, , 177-193.		0
609	Multiple Myeloma Associated with Dermatomyositis: A Short Report and Mini-Review. International Journal of Blood Research and Disorders, 2018, 5, .	0.2	1

#	Article	IF	Citations
611	Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma. Oncology & Hematology Review, 2019, 15, 87.	0.2	2
612	Hybrid models in biomedical applications. Computer Research and Modeling, 2019, 11, 287-309.	0.2	0
613	Complex cytogenetic research of cryptic chromosomal aberrations in patients with multiple myeloma. , 2019, 18, 50-59.	0.3	1
615	Amplification of the <i>MYC</i> gene in immunoglobulin light chain (AL) amyloidosis. Tenri Medical Bulletin, 2019, 22, 54-62.	0.1	0
619	Cancer-testis antigen MAGE-C1/â€ŠCT7 in multiple myeloma: literature review. Oncogematologiya, 2020, 15, 29-37.	0.1	0
620	Identification of glutathione Sâ€‘transferase Ï€ 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling. Oncology Letters, 2020, 19, 2153-2162.	0.8	1
621	Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. Oncology Research and Treatment, 2021, 44, 672-681.	0.8	25
622	Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma. Cancers, 2021, 13, 5518.	1.7	0
623	The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 12070.	1.8	3
624	Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents. Journal of the Advanced Practitioner in Oncology, 2013, 4, 307-21.	0.2	9
625	Methylation and mRNA expression levels of P15, death-associated protein kinase, and suppressor of cytokine signaling-1 genes in multiple myeloma. Iranian Journal of Basic Medical Sciences, 2016, 19, 755-62.	1.0	1
626	Single-cell atlas of splenocytes reveals a critical role of a novel plasma cellâ€'specific marker Hspa13 in antibody class-switching recombination and somatic hypermutation. Molecular Immunology, 2022, 141, 79-86.	1.0	5
627	The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma. Cancers, 2021, 13, 5687.	1.7	6
628	Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression. Signal Transduction and Targeted Therapy, 2021, 6, 400.	7.1	86
629	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Science Advances, 2021, 7, eabg9551.	4.7	49
630	Genome Instability in Multiple Myeloma: Facts and Factors. Cancers, 2021, 13, 5949.	1.7	17
631	(Distinct) origins of IgM myeloma. Blood, 2021, 138, 1914-1915.	0.6	2
632	Multiples Myelom. , 2016, , 1-17.		0

#	Article	IF	Citations
633	Molecular Profiling and Minimal Residual Disease Monitoring in Multiple Myeloma Patients: A Literature Review. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 436-443.	0.1	0
634	Plasma Cell Neoplasia. , 2020, , 283-297.		0
635	Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Frontiers in Oncology, 2021, 11, 819127.	1.3	10
636	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia, 2022, 36, 1078-1087.	3.3	13
637	Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma. Advanced Science, 2022, 9, e2104491.	5.6	13
638	Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions. Seminars in Oncology, 2022, , .	0.8	1
639	SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma. Blood Advances, 2022, 6, 2480-2495.	2.5	9
640	Comprehensive characterization of the epigenetic landscape in Multiple Myeloma. Theranostics, 2022, 12, 1715-1729.	4.6	10
641	Pathogenic signaling in multiple myeloma. Seminars in Oncology, 2022, 49, 27-40.	0.8	6
642	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treatment Reviews, 2022, 104, 102340.	3.4	21
643	B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. Journal of Translational Medicine, 2022, 20, 82.	1.8	7
644	Myeloma multiplex treatment and overall survival. Makedonsko Farmacevtski Bilten, 2022, 67, 79-90.	0.0	0
645	The Dynamics of Nucleotide Variants in the Progression from Lowâ€“Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach. Cancers, 2022, 14, 1035.	1.7	0
646	Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation. Journal of Clinical Investigation, 2022, 132, .	3.9	12
648	Novel microgel culture system as semi-solid three-dimensional in vitro model for the study of multiple myeloma proliferation and drug resistance. , 2022, 135, 212749.		7
649	Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways. BMC Medical Genomics, 2021, 14, 295.	0.7	5
650	Super Enhancer-Mediated Upregulation ofHJURPPromotes Growth and Survival of t(4;14)-Positive Multiple Myeloma. Cancer Research, 2022, 82, 406-418.	0.4	18
651	Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients. Cancers, 2021, 13, 6348.	1.7	1

#	Article	IF	Citations
652	Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Annals of Pharmacotherapy, 2022, 56, 951-957.	0.9	5
653	Key markers for diagnosis of minimal residual disease in multiple myeloma. , 2022, 21, 42-49.	0.3	2
654	<i>MAGE-C1</i> gene and mage-c1 protein expression comparison in primary multiple myeloma patients. Oncogematologiya, 2022, 17, 51-59.	0.1	0
655	Chromosome Territories in Hematological Malignancies. Cells, 2022, 11, 1368.	1.8	2
656	Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. Current Oncology, 2022, 29, 2954-2972.	0.9	4
657	Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2854-2864.	3.2	6
658	Multiple myeloma with high-risk cytogenetics and its treatment approach. International Journal of Hematology, 2022, 115, 762-777.	0.7	30
660	Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup. Life, 2022, 12, 812.	1.1	6
661	Pathogenesis and treatment of multiple myeloma. MedComm, 2022, 3, .	3.1	8
662	: A copy number clustering tool designed to refit and recalibrate the baseline region of tumorsâ€™ profiles. Computational and Structural Biotechnology Journal, 2022, 20, 3718-3728.	1.9	0
663	Linked-read whole-genome sequencing resolves common and private structural variants in multiple myeloma. Blood Advances, 2022, 6, 5009-5023.	2.5	2
664	The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nature Communications, 2022, 13, .	5.8	22
665	The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring â€œMultiple Myelomasâ€• Cancers, 2022, 14, 3271.	1.7	5
666	Identification of a drug-response gene in multiple myeloma through longitudinal single-cell transcriptome sequencing. IScience, 2022, 25, 104781.	1.9	2
667	Calorie restriction has no effect on bone marrow tumour burden in a Vk*MYC transplant model of multiple myeloma. Scientific Reports, 2022, 12, .	1.6	4
668	Novel intercepts for Multiple Myeloma. Journal of Pharmaceutical and Biological Sciences, 2022, 10, 22-28.	0.2	0
669	MULTIPLE MYELOMA: NARRATIVE REVIEW. , 2022, , 102-104.		0
670	Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling. Frontiers in Oncology, 0, 12, .	1.3	3

#	Article	IF	Citations
671	A Novel Integrated Approach for Cytogenomic Evaluation of Plasma Cell Neoplasms. Journal of Molecular Diagnostics, 2022, , .	1.2	0
673	First-in-Humans Evaluation of Safety and Dosimetry of⁶⁴Cu-LLP2A for PET Imaging. Journal of Nuclear Medicine, 2023, 64, 320-328.	2.8	8
674	Leukemias, Lymphomas, and Plasma Cell Disorders. , 2023, , 237-300.		0
675	The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma. Journal of Clinical Medicine, 2022, 11, 5461.	1.0	2
676	Comprehensive elaboration of circular RNA in multiple myeloma. Frontiers in Pharmacology, 0, 13, .	1.6	3
677	Development of a novel Brutonâ€™s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells. Frontiers in Pharmacology, 0, 13, .	1.6	4
678	IGHcytogenetic abnormalities can be detected in multiple myeloma by imaging flow cytometry. Journal of Clinical Pathology, 2023, 76, 763-769.	1.0	2
679	Integrative Analysis of Enrichment and Prognostic Value of Ferroptosis-related Genes and Pathways in Multiple Myeloma. Carcinogenesis, 0, , .	1.3	1
680	Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming. Molecular Cancer, 2022, 21, .	7.9	12
681	The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients. Frontiers in Oncology, 0, 12, .	1.3	3
684	Circulating Tumor DNA: Less Invasive, More Representative Method to Unveil the Genomic Landscape of Newly Diagnosed Multiple Myeloma Than Bone Marrow Aspirates. Cancers, 2022, 14, 4914.	1.7	2
685	NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial. Cancers, 2022, 14, 5169.	1.7	3
686	Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis. Frontiers in Pharmacology, 0, 13, .	1.6	8
687	Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing. Life Science Alliance, 2023, 6, e202201543.	1.3	4
688	An evolutionary machine learning for multiple myeloma using Runge Kutta Optimizer from multi characteristic indexes. Computers in Biology and Medicine, 2022, 150, 106189.	3.9	4
689	In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations. Journal of Clinical Oncology, 2023, 41, 1695-1702.	0.8	15
690	Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma. Discover Oncology, 2022, 13, .	0.8	2
691	Multiple Myeloma: Personalised Medicine Based on Pathogenesis. European Medical Journal (Chelmsford, England), 0, , 78-89.	3.0	1

#	Article	IF	Citations
692	Navigating the Changing Multiple Myeloma Treatment Landscape. European Medical Journal Hematology, 0, , 55-65.	0.0	0
693	The Pivotal Role of Proteasome Inhibition in Myeloma Treatment. European Medical Journal Hematology, 0, , 2-10.	0.0	0
694	Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma. International Journal of Molecular Sciences, 2022, 23, 15691.	1.8	1
695	Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma. European Journal of Haematology, 2023, 110, 296-304.	1.1	3
696	Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again. Hematology Reports, 2023, 15, 23-49.	0.3	1
697	Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China. Frontiers in Pharmacology, 0, 14, .	1.6	1
698	Hydroxychloroquine: Chemistry and Medicinal Applications. Heterocycles, 2023, 106, .	0.4	0
699	Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies. Pharmaceuticals, 2023, 16, 111.	1.7	7
700	Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood Cancer Journal, 2023, 13, .	2.8	8
701	Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway. Blood Cancer Journal, 2023, 13, .	2.8	3
702	Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma. Cell and Bioscience, 2023, 13, .	2.1	4
703	The genome of IMiD-refractory myeloma. Blood, 2023, 141, 560-561.	0.6	0
704	The presence of two light chain bands on immunofixation is associated with poor outcomes in newly diagnosed multiple myeloma patients. Annals of Hematology, 0, , .	0.8	0
705	Expression of integrin Î²-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics. Clinical Epigenetics, 2023, 15, .	1.8	2
706	Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene, 2023, 42, 994-1009.	2.6	6
707	Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma. Blood Cancer Journal, 2023, 13, .	2.8	4
708	Mouse models of human multiple myeloma subgroups. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	3
709	Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals, 2023, 16, 415.	1.7	7

#	Article	IF	Citations
711	Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A <scp>CMWPâ€EBMT</scp> study. European Journal of Haematology, 2023, 111, 181-190.	1.1	1
720	Malignant Brain and Spinal Tumors Originating from Bone or Cartilage. Advances in Experimental Medicine and Biology, 2023, , 477-506.	0.8	0
740	The Search for Cancer Drivers. Lecture Notes in Computer Science, 2024, , 145-171.	1.0	0